News

On 23 Oct. 2014 the clinical phase I trial Marsyas I, a prospective, single-Center, randomised, double-blinded, placebo controlled, dose finding phase I study in the indication skin wound healing was initiated.

On 25 April 2014 the Austrian Health Authority AGES issued the approval for the production of allogeneic and autologous APOSEC for clinical testing in the APOSEC GMP production facilty at the Blood Bank Linz.

Groundbreaking paper published in Biomaterials

Overexpression of GATA4, TGF-β3, MEF2C and HIF1-α contributes to improvement of infarct size in porcine model of chronic myocardial infarction, treated with percutaneous intramyocardial delivery of secretome of apoptotic white…

We are happy to announce that a European Patent for the treatment of skin wounds using supernatant of Peripheral Blood Mononuclear Cells (PBMCs) was granted to APOSCIENCE AG by the European Patent Office.

Die Prognose von Patienten mit kardiovaskulären Erkrankungen hat sich durch medikamentöse und interventionelle Therapien deutlich verbessert.

We cordially invite all students, scientists and other interested persons from within and outside the Medical University of Vienna to the Feature on Myocardial Regeneration.

Konrad Hoetzenecker was awarded a Young Investigator’s Award in Basic Science (YIA) of the European Society of Cardiology at the ESC Congress (25-29 September) in Munich for his recent publication.

On behalf of the local organizing committee we would like to propose the 2nd EACTS Cardiac and Pulmonary Regeneration meeting, in Vienna, Austria.